Ожирение: современные подходы к рациональной фармакотерапии
https://doi.org/10.21518/2079-701X-2016-3-72-78
Аннотация
Высокая распространенность ожирения представляет серьезную медико-социальную проблему и обусловлена урбанизацией, снижением физической активности и доступностью калорийной пищи. Во всем мире распространенность ожирения неуклонно растет на протяжении нескольких последних десятилетий: индекс массы тела увеличился на 0,4-0,5 за десятилетие во всем мире [1-3]. Данные выборочных исследований, проведенных в России, свидетельствуют, что в настоящее время не менее 30% трудоспособного населения нашей страны имеют избыточную массу тела и 25% - ожирение. Это позволило ВОЗ определить ожирение как неинфекционную эпидемию ХХ и XXI вв. [4-8].
Об авторах
M. Л. Максимов
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
С. С. Сологова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
О. В. Дралова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
Список литературы
1. Finucane M, Stevens G, Cowan M et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9-1 million participants. Lancet, 2011, 377: 557-567.
2. Williams Textbook of Edocrinology, edition 11 2009.
3. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care, 2001, 24(4): 683-9.
4. Демидова Т.Ю., Круглова ЕЛ. Ожирение как ключевая и модифицируемая причина развития сахарного диабета 2 типа. РМЖ, 2009, 17, 7.
5. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children : quick reference guide 1: for local authorities, schools and early years providers, workplaces and the public. London: National Institute for Health and Clinical Excellence, 2006.
6. Snow V, Barry P, Fitterman N et al. Pharmaco-logic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2005, 142(7): 525-31.
7. Ayyard and Anderson. Ob Rev, 2000, 1: 113-9.
8. http//www.who.i nt/featu res/fa ctfi les/obesity/ ru/index.html.
9. Lau DC, Douketis JD, Morrison KM et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ, 2007, 176: S1-S13.
10. Global Health Risks: mortality and burden of disease attributable to selected major risks 2009. http//www.who.int/healthinfo/global_ burden_disease/global_health_risks/en/index. html Accessed November 12, 2011.
11. Obesity and overweight Fact sheet №311. Updated March 2011 http//www.who.int/medi-acentre/factsheets/fs311/en/index.html Accessed November 15, 2011.
12. AHA/ACCAOS Guideline for the Management of Overweight and Obesity in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol., 2014, 63(25_PA): 2985-3023. doi:10.1016/j.jacc.2013.11.004.
13. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) The European Society of Cardiology 2012. Eur Heart J, 2013, 34: 3035-3087.
14. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano FO, Grassi G, Zanchetti A, Sega R. Metabolic syndrome in the Pressioni Arteriose Moni-torate E Loro Associazioni (PAMELA) study: daily life blood-pressure, cardiac damage, and prognosis. Hypertension, 2007, 49: 40-47.
15. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpussalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288: 2709-2716.
16. Garrison RJ, Kannel WB, Stokes J et al: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med, 1987, 16: 235-251.
17. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24: 683-9.
18. McFarlane SI, Banerij M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab, 2001, 86: 713-8.
19. Rahmouni K, Correia MLG, Haynes WG et al. Obesety-associated hypertension. New insights into mechanisms. Hypertension, 2005, 45: 9-14.
20. Mule G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, Mongiovi R, Mezzatesta G, An-dronico G, Cerasola G. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med, 2005, 257: 503-513.
21. Schilacci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G, Franklin SS, Manna-rino E. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension, 2005, 45: 1978-1982.
22. Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sala C, Sampieri L, Magrini F, Zanchetti A. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens, 2005, 23: 875-882.
23. Kavamoto R, Tomita H, Oka Y, Kodama A, Kamitani A. Metabolic syndrome amplifi es the LDL-cholesterol associated increases in carotid atherosclerosis. Intern med, 2005, 44: 1232-1238.
24. Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sala C, Zanchetti A. Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. J Hypertens, 2005, 23: 1589-1595.
25. Prevention of cardiovascular disease -Guidance on the prevention of cardiovascular disease at the population level. NICE Public Health Guideline (June 2010).
26. Bray GA. Contemporary diagnosis and management of obesity. MD, 1998, 657.
27. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res., 1998, 6(suppl): 51S-210S.
28. Obesity: guidance on the prevention, identifi cation, assessment and management of overweight and obesity in adults and children : quick reference guide 1 : for local authorities, schools and early years providers, workplaces and the public. London: National Institute for Health and Clinical Excellence, 2006.
29. Snow V, Barry P, Fitterman N, Oaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2005, Apr 5, 142(7): 525-531.
30. Ayyard and Anderson., Obesity Review, 2000, 1: 113-9.
31. Demidova T.Y., Kruglova E.L. Obesity as the key and modifiable cause of type 2 diabetes. RMZ, 2009, 17, 7.
32. Laaksonen DE, Lindstrom J, Lakka TA et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes, 2005, 54: 158-165.
33. National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity. Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health, October 2000. NIH publication No. 00-4084.
34. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation, 2012, 125: 1695-1703.
35. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24(4): 683-689.
36. http://english.prescrire.org/en/79/207/46302/2374/1884/SubReportDetails.aspx.
37. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care, 2008, 31(suppl 2): S269-S277.
38. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 2007, 369: 71-7.
39. Grundy SM, Hansen B, Smith SC et al. Clinical Management of Metabolic Syndrome. Circulation, 2004, 109: 551-556.
40. Atkinson RL, Blank RC, Loper JF et al. Combined drug treatment of obesity. Obes. Res., 1995, 3(Suppl. 4): 497-500.
41. Questions and answers on the suspension of medicines containing sibutramine Outcome of a procedure under Article 107 of Directive 2001/83/EC6 August 2010 EMA/808179/2009 rev EMEA/H/A-107/1256 ttp://www.ema.europa.eu/docs/en_GB/document_library/ Referrals_document/ Sibutramine_107/WC500094238.pdf.
42. Sibutramine (Meridia) withdrawn. Med Lett Drugs Ther., 2010, Nov 1, 52(1350): 88.
43. Williams G. Withdrawal of sibutramine in Europe. BMJ, 2010, 340: 824.
44. Jardiance™: instruction for use. Registration certificate LP- 002735.
45. Invokana™: instruction for use. Registration number 002977.
46. Forxiga™: instruction for use. Registration number: LP-002596.
47. Zhi J, Melia AT, Eggers H et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in health human volunteers. J. Clin. Pharmacol., 1995, 35: 1103-8.
48. Xenical: instruction for medical use.
49. Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs, 2006, 66(12): 1625-1656.
50. Maksimov M.L. Xenical in the combination treatment of patients with overweight and obesity. Ozhirenie i Metabolizm, 2010, 1: 34-39.
51. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27(1): 155-61.
52. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab, 2005, 7(6): 699-708.
53. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL -- Primary Health Care Trial. Diabetes Obes Metab, 2005, 7(1): 21-7.
54. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord, 2001, 25(11): 1713-21.
55. Kelley DE, Kuller LH, McKolanis TM et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care, 2004, 27(1): 33-40.
56. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care, 1998, 21(8): 1288-94.
57. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
58. Diabetes Care, 2002, 25(6): 1033-41.
59. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care, 2002, 25(7): 1123-8.
60. Maksimov M.L. The problem of choosing between the original and generic drug in the treatment of patients with overweight and obesity. Ozhirenie i Metabolizm, 2013, 3, 19-26.
61. Max H Pittler and Edzard Ernst Dietary supplements for body-weight reduction: a systematic Review. Am J Clin Nutr, 2004, 79: 529-36.
62. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. Med J Aust, 1999, 171: 604-8.
63. Nortier JL, Martinez MCM, Schmeiser HH. Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi). N. Engl J Med, 2000, 342: 1686-1692.
64. FDA Warns About Products Containing Gamma Butyrolactone or GBL and Asks Companies to Issue a Recall (FDA Talk Paper, January 21, 1999). http://vm.cfsan.fda.gov/~lrd/tpgbl.html.
65. FDA Public Health Advisory: Risk of Drug Interactions with St. John's Wort and Indinavir and Other Drugs. February 10, 2000. http://www.fda.gov/cder/drug/advisory/stjwort.htm.
66. Supplements Associated with Illnesses and Injuries. U. S. Food and Drug Administration FDA Consumer September -- October 1998 FDA Consumer magazine (September-October 1998). http://www.cfsan.fda.gov/~dms/fdsuppch.html.
67. Impurities Confirmed in 5-Hydroxy-L-Tryptophan (5HTP) (FDA Talk Paper, September 1, 1998). http://vm.cfsan.fda.gov/~lrd/tp5htp.html
68. FDA Warns Consumers Not to Use the Dietary Supplement LipoKinetix November 19, 2001. http://www.cfsan.fda.gov/~dms/ds-lipo.html.
69. FDA Warns Against Drug Promotion of "Herbal Fen-Phen" (FDA Talk Paper, November 6, 1997). http://vm.cfsan.fda.gov/~lrd/tpfenphn.html.
70. http://www.fda.gov/downloads/NewsEvents/PublicHealthFocus/UCM160672.pdf.
Рецензия
Для цитирования:
Максимов MЛ, Сологова СС, Дралова ОВ. Ожирение: современные подходы к рациональной фармакотерапии. Медицинский Совет. 2016;(3):72-78. https://doi.org/10.21518/2079-701X-2016-3-72-78
For citation:
Maksimov ML, Sologova SS, Dralova OV. Obesity: current approaches to adequate pharmacotherapy. Meditsinskiy sovet = Medical Council. 2016;(3):72-78. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-72-78
Просмотров:
739
Послать статью по эл. почте 